RXST · Q3 revenue -19% YoY to $24.6M

RxSight reported Q3 2026 total revenue of $24.6M, down 19% YoY from $30.3M, missing the $27.2M consensus. Gross margin contracted to 73.6% from 79.9% due to higher inventory reserves and costs. The company highlighted commercial restructuring and the Alcon collaboration, but the top-line decline and wider losses are the dominant signals.

• Total revenue of $24.6M, down 19% from $30.3M in Q3 2025
• Gross margin fell to 73.6% from 79.9%, driven by higher inventory reserves and costs
• Cash and investments of $254.7M including $60M from Alcon collaboration
• Revenue missed consensus of $27.2M; adjusted EPS missed consensus of $(0.19)